Evidence map›Paper›PMID 22185448›Full record

ReviewFuture cardiology2012

Targeting cardiovascular disease with novel SIRT1 pathways.

Zhao Zhong Chong, Shaohui Wang, Yan Chen Shang, Kenneth Maiese

Open access · greenAbstract readReview
In one paragraph

Review in Future cardiology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 63 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
63citing papers in PubMed, 1 pooled it
3.6field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

63 citing papers in PubMed, 1 synthesis or guideline pooled it, 117 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Association ofHealth science reports · 2025
    Article
  6. Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Targeting Immune Senescence in Atherosclerosis.International journal of molecular sciences · 2022
    Review
  12. Article
  13. Article
  14. Article
  15. A Network Pharmacology Study to Explore the Underlying Mechanism of Safflower (Evidence-based complementary and alternative medicine : eCAM · 2022
    Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Review

3 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 4 countries.

Zhao Zhong ChongLaboratory of Cellular & Molecular Signaling, Department of Neurology & Neurosciences, Cancer Center, University of Medicine & Dentistry, New Jersey Medical School, Newark, NJ 07101, USA.
Shaohui Wang
Yan Chen Shang
Kenneth Maiese
Toxicologie, Pharmacologie et Signalisation Cellulaire · FRRutgers New Jersey Medical SchoolSchlumberger (Ireland) · IE

Funding

RESEARCH CORE-- SIGNAL TRANSDUCTIONP30ES006639 · NIEHS · WAYNE STATE UNIVERSITY · PI RUNGE-MORRIS, MELISSA A · 1994 to 2008
$13.1M
Impacting Oxidative Stress and Cell Injury through Novel Pathways of the Wnt GeneR01NS053946 · NINDS · WAYNE STATE UNIVERSITY · PI MAIESE, KENNETH · 2007 to 2011
$2.4M
NIEHS NIH HHS P30 ES006639NIEHS NIH HHS P30 ES06639NINDS NIH HHS R01 NS053946
6 · The paper itself

Abstract

Sirtuin (the mammalian homolog of silent information regulation 2 of yeast Saccharomyces cerevisiae) 1 (SIRT1), a NAD-dependent histone deacetylase, has emerged as a critical regulator in response to oxidative stress. Through antagonism of oxidative stress-induced cell injury and through the maintenance of metabolic homeostasis in the body, SIRT1 can block vascular system injury. SIRT1 targets multiple cellular proteins, such as peroxisome proliferator-activated receptor-γ and its coactivator-1α, forkhead transcriptional factors, AMP-activated protein kinase, NF-κB and protein tyrosine phosphatase to modulate intricate cellular pathways of multiple diseases. In the cardiovascular system, activation of SIRT1 can not only protect against oxidative stress at the cellular level, but can also offer increased survival at the systemic level to limit coronary heart disease and cerebrovascular disease. Future knowledge regarding SIRT1 and its novel pathways will open new directions for the treatment of cardiovascular disease as well as offer the potential to limit disability from several related disorders.

Indexed as

AMP-Activated Protein KinasesCardiomyopathy, HypertrophicCoronary Artery DiseaseCytoprotectionHeat-Shock ProteinsHumansNF-kappa BOxidative StressPeroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alphaPPAR gammaSignal TransductionSirtuin 1Transcription FactorsAMP-Activated Protein KinasesHeat-Shock ProteinsNF-kappa BPeroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alphaPPAR gammaPPARGC1A protein, humanSirtuin 1Transcription Factors

Identifiers

PMID22185448
PMCPMC3254055
OpenAlexW2154202727

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.